BEUDAMED
    FDA Adverse Event Injury Summary report: N

    OPTRELL MAPPING CATHETER WITH TRUEREF TECHNOLOGY

    MDR report key: 22710649 · Received August 4, 2025

    Report

    Report Number
    2029046-2025-02552
    Event Type
    Injury
    Date Received
    August 4, 2025
    Date of Event
    July 7, 2025
    Manufacturer
    BIOSENSE WEBSTER INC
    Product Code
    DRF
    UDI-DI
    10846835025828
    PMA / PMN Number
    K230253
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    JA
    Reporter Occupation
    OTHER
    Health Professional
    N

    Narratives

    Additional Manufacturer Narrative · 0

    ON 29-JUL-2025, THE BWI PRODUCT ANALYSIS LAB RECEIVED THE COMPLAINT DEVICE FOR EVALUATION. THE PRODUCT ANALYSIS HAS BEGUN BUT IS NOT COMPLETED AT THIS TIME. WHEN THE INVESTIGATIONAL ANALYSIS HAS BEEN COMPLETED, A SUPPLEMENTAL 3500A REPORT WILL BE SUBMITTED. THIS REPORT IS BEING SUBMITTED PURSUANT TO THE PROVISIONS OF 21 CFR, PART 803. THIS REPORT MAY BE BASED ON INFORMATION WHICH HAS NOT BEEN INVESTIGATED OR VERIFIED PRIOR TO THE REQUIRED REPORTING DATE. THIS REPORT DOES NOT REFLECT A CONCLUSION BY BIOSENSE WEBSTER INC., OR ITS EMPLOYEES THAT THE REPORT CONSTITUTES AN ADMISSION THAT THE PRODUCT, BIOSENSE WEBSTER INC., OR ITS EMPLOYEES CAUSED OR CONTRIBUTED TO THE POTENTIAL EVENT DESCRIBED IN THIS REPORT. IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL REPORT, A FOLLOW-UP REPORT WILL BE FILED AS APPROPRIATE. MANUFACTURER'S REF. # (B)(4).

    Additional Manufacturer Narrative · 0

    IT WAS REPORTED THAT A PATIENT UNDERWENT A CARDIAC ABLATION PROCEDURE WITH A OPTRELL MAPPING CATHETER WITH TRUEREF TECHNOLOGY AND THE PATIENT EXPERIENCED CARDIAC TAMPONADE THAT REQUIRED MEDICATION. IT WAS REPORTED THAT THE OPTRELL MAPPING CATHETER WITH TRUEREF TECHNOLOGY (OPTRELL)GAVE A SENSOR ERROR FOR 20 POLE A ON THE CARTO 3 SYSTEM. RECONNECTION AND CABLE REPLACEMENT DID NOT IMPROVE THE SITUATION. THEY INTENDED TO REPLACE THE OPTRELL WITH ANOTHER NEW ONE, HOWEVER, A CARDIAC TAMPONADE OCCURRED. THE PROCEDURE WAS INTERRUPTED, AND THE PATIENT WAS MANAGED WITH AN INTRAVENOUS DRIP AND IMPROVEMENT WAS OBSERVED WITH THE ADMINISTRATION OF VASOPRESSOR MEDICATIONS. THE PHYSICIAN'S JUDGMENT ON HEALTH HAZARD WAS THAT IT WAS NON-SERIOUS (MODERATE/MINOR). THERE WAS NO EXTENDED HOSPITALIZATION. NO CAUSAL RELATIONSHIP BETWEEN THE EVENT AND THE PRODUCT. THERE WERE NO ABNORMALITIES OBSERVED PRIOR TO OR DURING USE OF THE PRODUCT. NO ABLATION WAS PERFORMED. ADVERSE EVENT OCCURRED DURING THE MAPPING PHASE. ADDITIONAL INFORMATION RECEIVED INDICATING THE ENERGY DELIVERED WAS RADIOFREQUENCY (RF). THE PATIENT DID NOT REQUIRE CARDIAC SURGERY. THE SECOND OPTRELL CATHETER, QDOT MICRO AND SOUNDSTAR CATHETERS WERE NOT USED SINCE CARDIAC TAMPONADE OCCURRED. THE OUTCOME OF THE ADVERSE EVENT WAS REPORTED AS FULLY RECOVERED (NO RESIDUAL EFFECTS). THE PATIENT WAS DISCHARGED FROM THE HOSPITAL. DEVICE EVALUATION DETAILS: THE DEVICE WAS RETURNED TO JOHNSON & JOHNSON MEDTECH (J&J) FOR EVALUATION. A VISUAL INSPECTION AND REVISION OF ALL FEATURES WERE PERFORMED FOLLOWING J&J PROCEDURES. VISUAL ANALYSIS REVEALED NO DAMAGE OR ANOMALIES ON THE DEVICE. THE DEVICE WAS CONNECTED TO THE CARTO 3 SYSTEM AND IT WAS VISUALIZED AND RECOGNIZED CORRECTLY; NO MAGNETIC ISSUES WERE OBSERVED. THEN, A FUNCTIONAL TEST WAS PERFORMED, AND NO ISSUES WERE OBSERVED DURING THE PRODUCT INVESTIGATION. A MANUFACTURING RECORD EVALUATION WAS PERFORMED FOR THE FINISHED DEVICE BATCH NUMBER, AND NO INTERNAL ACTIONS WERE IDENTIFIED. THE MAGNETIC ISSUE REPORTED BY THE CUSTOMER COULD NOT BE REPLICATED DURING THE PRODUCT INVESTIGATION, OTHER ISSUES OR CIRCUMSTANCES MAY HAVE OCCURRED DURING THE USAGE OF THE DEVICE THAT COMPROMISED ITS PERFORMANCE. NO MALFUNCTION WAS OBSERVED DURING THE INVESTIGATION. THE ROOT CAUSE OF THE ADVERSE EVENT REMAINS UNKNOWN. THE INSTRUCTION FOR USE (IFU) CONTAINS THE FOLLOWING WARNINGS AND PRECAUTIONS: CAREFUL MANIPULATION MUST BE PERFORMED IN ORDER TO AVOID CARDIAC DAMAGE, PERFORATION, OR TAMPONADE. CATHETER ADVANCEMENT AND PLACEMENT THROUGH A GUIDING SHEATH SHOULD BE DONE USING A COMBINATION OF VISUAL AIDS AVAILABLE, FLUOROSCOPIC GUIDANCE AND/OR INTRACARDIAC ULTRASOUND. IN ADDITION, EXTRA CARE SHOULD BE TAKEN WHILE INSERTING, ASPIRATING, AND MANIPULATING THE GUIDING SHEATH. PRIOR TO REMOVING OR REPOSITIONING THE CATHETER, USE DIRECT IMAGING GUIDANCE SUCH AS FLUOROSCOPY OR ULTRASOUND TO CONFIRM THAT THE SPINE ASSEMBLY IS NOT ENTANGLED WITH ANOTHER CATHETER OR WITH AN ANATOMICAL STRUCTURE. EXERCISE CAUTION WHEN MANEUVERING THE CATHETER NEAR THE VALVULAR APPARATUS TO AVOID ENTANGLEMENT OR ENTRAPMENT WHICH MAY RESULT IN THE NEED FOR SURGICAL INTERVENTION. AS PART OF JOHNSON & JOHNSON MEDTECH'S QUALITY PROCESS, ALL DEVICES ARE MANUFACTURED, INSPECTED, AND RELEASED TO APPROVED SPECIFICATIONS. IF ADDITIONAL INFORMATION IS RECEIVED REGARDING THIS EVENT, A SUPPLEMENTAL 3500A REPORT WILL BE SUBMITTED TO THE FDA. MANUFACTURER'S REF. # (B)(4).

    Description of Event or Problem · 0

    IT WAS REPORTED THAT A PATIENT UNDERWENT A CARDIAC ABLATION PROCEDURE WITH A OPTRELL MAPPING CATHETER WITH TRUEREF TECHNOLOGY AND THE PATIENT EXPERIENCED CARDIAC TAMPONADE THAT REQUIRED MEDICATION. IT WAS REPORTED THAT THE OPTRELL MAPPING CATHETER WITH TRUEREF TECHNOLOGY (OPTRELL)GAVE A SENSOR ERROR FOR 20 POLE A ON THE CARTO 3 SYSTEM. RECONNECTION AND CABLE REPLACEMENT DID NOT IMPROVE THE SITUATION. THEY INTENDED TO REPLACE THE OPTRELL WITH ANOTHER NEW ONE, HOWEVER, A CARDIAC TAMPONADE OCCURRED. THE PROCEDURE WAS INTERRUPTED, AND THE PATIENT WAS MANAGED WITH AN INTRAVENOUS DRIP AND IMPROVEMENT WAS OBSERVED WITH THE ADMINISTRATION OF VASOPRESSOR MEDICATIONS. THE PHYSICIAN'S JUDGMENT ON HEALTH HAZARD WAS THAT IT WAS NON-SERIOUS (MODERATE/MINOR). THERE WAS NO EXTENDED HOSPITALIZATION. NO CAUSAL RELATIONSHIP BETWEEN THE EVENT AND THE PRODUCT. THERE WERE NO ABNORMALITIES OBSERVED PRIOR TO OR DURING USE OF THE PRODUCT. NO ABLATION WAS PERFORMED. ADVERSE EVENT OCCURRED DURING THE MAPPING PHASE. ADDITIONAL INFORMATION RECEIVED INDICATING THE ENERGY DELIVERED WAS RADIOFREQUENCY (RF). THE PATIENT DID NOT REQUIRE CARDIAC SURGERY. THE SECOND OPTRELL CATHETER, QDOT MICRO AND SOUNDSTAR CATHETERS WERE NOT USED SINCE CARDIAC TAMPONADE OCCURRED. THE OUTCOME OF THE ADVERSE EVENT WAS REPORTED AS FULLY RECOVERED (NO RESIDUAL EFFECTS). THE PATIENT WAS DISCHARGED FROM THE HOSPITAL. SINCE THE PHYSICIAN REPORTED THAT THERE WAS NO CAUSAL RELATIONSHIP BETWEEN THE ADVERSE EVENT AND THE PRODUCT, IT IS IMPLIED THAT THE MAGNETIC SENSOR MALFUNCTION WITH THE CATHETER DID NOT CAUSE THE ADVERSE EVENT. HOWEVER, THE EVENT CANNOT BE DISASSOCIATED FROM THE OPTRELL MAPPING CATHETER WITH TRUEREF TECHNOLOGY SINCE THE EVENT OCCURRED DURING MAPPING PHASE AND THE OPTRELL MAPPING CATHETER WITH TRUEREF TECHNOLOGY WAS INSIDE THE PATIENT'S BODY.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    2804014 OPTRELL MAPPING CATHETER WITH TRUEREF TECHNOLOGY CATHETER, ELECTRODE RECORDING, OR PROBE, ELECTRODE RECORDING DRF BIOSENSE WEBSTER INC 31441850M 10846835025828

    Patients

    Seq Age Sex Outcome Treatment
    1 NA Female Required Intervention| L OPTRELL, 36 ELECTRODES, D-F.| QDOT MICRO, BI, TC, D-D.| UNK_SOUNDSTAR.